Building a Sustainable BioPharma Industry--the European Way

Europe's financing and regulatory environment means that it has been, and will continue to be, very difficult to build Amgen-style big biotech from scratch here. But a sustainable industry of large biotechs is nevertheless emerging-mostly through the transformation of existing big or mid-sized pharma assets. Big Pharma spin outs, created to circumvent prohibitive labor laws, and small, R&D-embracing in-licensing firms are two important sources. But so are the mid-sized drug firms--another largely European phenomenon. The potential transformation of UCB into a big biotech, triggered by the acquisition of Celltech, is the most recent example.

It's easy to be skeptical about the prospects for a sustainable biopharma industry in Europe: VC financing is only a sixth of that in the US, and is becoming conditional on marketed, or near-to-market products. IPOs are few and far between, and performing shakily. Drug prices are being slashed, along with reimbursement levels, US acquirers are on the prowl, and increasing numbers of European firms are setting up subsidiaries in the US—in some cases as a prelude to transferring their operations there. (See "European Financing: the Money's There, But How Do You Get It?" this issue [A#2004600086], and "The US: To Go or Not to Go?" this issue.[A#2004600086])

But Europe's challenges are surmountable, according to a group of senior industry executives and experts gathered at Windhover's Euro-Biotech Forum...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Global Vision

More from In Vivo